Source: International Congress 2014 – The more in-depth classification of lung cancer: relevance for patients and science



Rating:

Share or cite this content

Citations should be made in the following way:
A. Cortot (Lille, France). Integration of molecular testing in the classification of NSCLC: the French experience. International Congress 2014 – The more in-depth classification of lung cancer: relevance for patients and science

Member's Comments

No comment yet.

Related content which might interest you: Eminence or evidence based ? – personalised diagnostic-therapeutic sequences in a molecular altered advanced NSCLC patient Source: International Congress 2017 – GR2 Lung Cancer Grand Round Year: 2017 New findings in the molecular biology of lung cancer: clinical application Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Is EBUS sampling adequate for molecular testing in patients with advanced NSCLC? Source: Virtual Congress 2020 – Current and contemporary practices in endobronchial ultrasound Year: 2020 Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 A new WHO classification for lung cancer after 11 years: clinical implications Source: International Congress 2015 – Lung cancer pathology Year: 2015 History of lung adenocarcinoma classification. Overview and pathology of new ERS/ATS/IASLC proposal Source: Annual Congress 2009 - The new ERS/ATS/IASLC classification of lung adenocarcinoma: practice update Year: 2009 Patient perspectives and experience on the diagnostic pathway of lung cancer – a qualitative study Source: International Congress 2018 – Contemporary respiratory care: symptoms, the role of the nurse and the organisation of care Year: 2018 Single Slide Assessment: the future of molecular testing in lung cancer? Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 A new classification system for NSCLC: what do we expect from imaging? Source: Annual Congress 2009 - The new classification system of nonsmall cell lung cancer: a challenge for imaging Year: 2009 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Optimization of cfDNA routine use for NSCLC genomic alteration analysis Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease Year: 2016 Novel survey tool used to assess priorities of lung cancer patients and carers Source: International Congress 2015 – Quality management in lung cancer Year: 2015 New treatment concepts in stage IV NSCLC: personalized multidisciplinary approaches Source: Virtual Congress 2021 – Hot topics in thoracic oncology Year: 2021 Regional deployment of collaborative lung function testing: is the Catalan experience transferable to other settings? Source: International Congress 2016 – Implementation of collaborative lung function testing Year: 2016 The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection Source: Eur Respir J 2002; 20: 464-479 Year: 2002 Molecular biology of advanced NSCLC and survival: seeking the best therapy Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration Source: Eur Respir J 2009; 34: 1477-1486 Year: 2009